60 Degrees Pharmaceuticals, Inc SXTP

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
42/100
Developing

Ranked against 712 peers in Biotechnology

About 60 Degrees Pharmaceuticals, Inc

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in … Full SXTP analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 93.1th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.13), raising refinancing risk.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.33), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
31
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where SXTP ranks in Biotechnology

60 Degrees Pharmaceuticals, Inc ranks #341 of 713 scored companies in Biotechnology by moat score — the top 48%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
337 Rocket Pharmaceuticals, Inc. RCKT 43/100 Developing
338 Vaxcyte, Inc. PCVX 43/100 Developing
339 Chemomab Therapeutics Ltd. CMMB 42/100 Developing
340 Solid Biosciences Inc. SLDB 42/100 Developing
341 60 Degrees Pharmaceuticals, Inc SXTP 42/100 Developing
342 BioLineRx Ltd. BLRX 42/100 Developing
343 Prelude Therapeutics Incorporat PRLD 42/100 Developing
344 Fate Therapeutics, Inc. FATE 42/100 Developing
345 ARS Pharmaceuticals, Inc. SPRY 42/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How SXTP scores on the Corporate Default defenses

Pricing Power

Score 31 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 40 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 48 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 77 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 25 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 31 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding SXTP's moat

What is 60 Degrees Pharmaceuticals, Inc's moat score?

60 Degrees Pharmaceuticals, Inc (SXTP) scores 42 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #341 of 713 scored companies in Biotechnology, the top 48%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (77/100) and its weakest is Resilience (25/100).

How does 60 Degrees Pharmaceuticals, Inc compare with other Biotechnology companies?

60 Degrees Pharmaceuticals, Inc ranks #341 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Solid Biosciences Inc. (SLDB) at 42 just above it and BioLineRx Ltd. (BLRX) at 42 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is 60 Degrees Pharmaceuticals, Inc scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for 60 Degrees Pharmaceuticals, Inc?

The Corporate Default template measures 6 defenses, and SXTP scores: Pricing Power (31), Cost Advantage (40), Customer Stickiness (48), Capital Efficiency (77), Resilience (25), Scale & Market Position (31). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000